Active	Status	Sponsor type	Region	Phase	Filter
12 Active 3 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kaffenberger, Jessica
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata Apr 2021 - Apr 2021: Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata From BRAVE-AA1 trial for alopecia areata Oct 2020 - Oct 2020: From BRAVE-AA1 trial for alopecia areata	Active, not recruiting	2/3	824	Japan, US, RoW	Baricitinib, LY3009104, Placebo	Eli Lilly and Company, Incyte Corporation	Alopecia Areata	02/21	01/25
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE	Recruiting	2	532	Europe, Japan, US, RoW	M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA	Systemic Lupus Erythematosus	04/25	04/25
NCT05590247: Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis	Recruiting	N/A	60	US	Intermittent Fasting Diet, fasting, intermittent energy restriction	Ohio State University, National Psoriasis Foundation	Psoriasis, Psoriatic Arthritis	03/25	09/25
NCT03146676: The Ohio State University Dermatology Biorepository	Recruiting	N/A	175	US		Ohio State University	Hidradenitis Suppurativa	12/30	12/30
Kaffenberger, Benjamin
NCT04582383: Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne	Recruiting	4	400	US	Spironolactone, Doxycycline Hyclate	University of Pennsylvania	Acne	12/25	07/26
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus	Recruiting	2/3	474	Europe, Canada, Japan, US, RoW	Litifilimab, BIIB059, Placebo	Biogen, Biogen Idec Research Limited	Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus	10/26	12/27
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients	Active, not recruiting	2	170	US, RoW	OQL011, Vehicle Ointment	OnQuality Pharmaceuticals (USA) LLC	Hand-Foot Skin Reaction (HFSR)	02/24	06/24
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE) Jul 2024 - Sep 2024 : Data for CLE	Active, not recruiting	2	532	Europe, Japan, US, RoW	Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Systemic Lupus Erythematosus	11/24	12/24
NCT05590247: Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis	Recruiting	N/A	60	US	Intermittent Fasting Diet, fasting, intermittent energy restriction	Ohio State University, National Psoriasis Foundation	Psoriasis, Psoriatic Arthritis	03/25	09/25
NCT05984654: Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum	Recruiting	N/A	10	US	Platelet rich plasma therapy	Ohio State University	Pyoderma Gangrenosum	12/26	06/27
NCT03146676: The Ohio State University Dermatology Biorepository	Recruiting	N/A	175	US		Ohio State University	Hidradenitis Suppurativa	12/30	12/30
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC	Recruiting	N/A	15000	Europe, Canada, US		Target PharmaSolutions, Inc.	Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria	12/50	12/50